Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers
No hay miniatura disponible
Archivos
Fecha
2023
Profesor/a Guía
Facultad/escuela
Idioma
en
Título de la revista
ISSN de la revista
Título del volumen
Editor
Frontiers Media S.A.
Nombre de Curso
Licencia CC
CC BY 4.0 DEED Attribution 4.0 International
Licencia CC
https://creativecommons.org/licenses/by/4.0/
Resumen
For many years, luteinizing hormone-releasing hormone or gonadotropin-releasing hormone (GnRH) analogs have been used to treat androgen or estrogen-dependent tumors. However, emerging evidence shows that the GnRH receptor (GnRH-R) is overexpressed in several cancer cells, including ovarian, endometrial, and prostate cancer cells, suggesting that GnRH analogs could exert direct antitumoral actions in tumoral tissues that express GnRH-R. Another recent approach based on this knowledge was the use of GnRH peptides for developing specific targeted therapies, improving the delivery and accumulation of drugs in tumoral cells, and decreasing most side effects of current treatments. In this review, we discuss the conventional uses of GnRH analogs, together with the recent advances in GnRH-based drug delivery for ovarian, breast, and prostatic cancer cells. Copyright © 2023 Garrido, Hernandez, Vega, Araya and Romero.
Notas
Indexación: Scopus.
Palabras clave
Breast cancer, GnRH, Ovarian cancer, Prostatic cancer, Targeted therapy
Citación
Frontiers in Endocrinology. Volume 14. 2023. Article number 1143261
DOI
10.3389/fendo.2023.1143261